Skip to main content

Cancer epigenetics and diagnostics

Section information

Section Editors : Carmen Jeronimo and Maria Berdasco

Associate Editors : Nita Ahuja, James Chim (haematological-based cancers only); Jim Davie, James Flanagan, Mario Fraga, Michéle Hoffmann, Bozena Kaminska (gliomas), Gwen Lomberk, Graham K Packham, Arpad Patai (colorectal/GI cancers), Qian Tao, Raul Urrutia, Keishi Yamashita

The development of genome-wide techniques has rapidly improved the comprehensive knowledge of epigenetic alterations in cancer. Currently, a vast number of genes and their associated molecular pathways that show epigenetic differences between normal and tumoral cells have been identified, emphasizing the crucial role of epigenetic factors in cancer etiology and progression.  This section publishes original epigenetic research focused on the identification of epigenetic biomarkers associated with cancer diagnosis or tumor progression. Manuscripts on epigenetic biomarkers leading to a better definition of therapy response are also accepted (pharmacoepigenetics). Submissions on reports from human clinical trials providing insights on the clinical application of epigenetic biomarkers are welcomed.

Page 1 of 8

  1. Despite the efforts to describe the molecular landscape of esophageal adenocarcinoma (EAC) and its precursor lesion Barrett’s esophagus (BE), discrepant findings are reported. Here, we investigated the prevale...

    Authors: Rita Pinto, Tobias Hauge, Marine Jeanmougin, Heidi D. Pharo, Stine H. Kresse, Hilde Honne, Sara B. Winge, May-Britt Five, Theresa Kumar, Tom Mala, Truls Hauge, Egil Johnson and Guro E. Lind
    Citation: Clinical Epigenetics 2022 14:77
  2. Ovarian cancer (OC) is a highly lethal gynecologic cancer, and it is hard to diagnose at an early stage. Clinically, there are no ovarian cancer-specific markers for early detection. Here, we demonstrate the u...

    Authors: Huaiwu Lu, Yunyun Liu, Jingyu Wang, Shaliu Fu, Lingping Wang, Chunxian Huang, Jing Li, Lingling Xie, Dongyan Wang, Dan Li, Hui Zhou and Qunxian Rao
    Citation: Clinical Epigenetics 2022 14:74
  3. Alterations in histone modifications have been reported to be related to tumorigenicity and tumor progression. However, whether histone modification can aid the classification of patients or influence clinical...

    Authors: Rui Zhou, Fuli Xie, Kuncai Liu, Xuee Zhou, Xuemei Chen, Jinzhang Chen, Shaoyan Xi, Zhenhua Huang and Xiaoxiang Rong
    Citation: Clinical Epigenetics 2022 14:70
  4. Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) analysis represents a liquid biopsy approach for real-time monitoring of tumor evolution. DNA methylation is considered to be an early event in ...

    Authors: Α. Markou, D. Londra, V. Tserpeli, Ι. Kollias, E. Tsaroucha, I. Vamvakaris, K. Potaris, I. Pateras, Α. Kotsakis, V. Georgoulias and Ε. Lianidou
    Citation: Clinical Epigenetics 2022 14:61
  5. LINC00114 could promote the development of colorectal cancer, but its mechanism has been rarely discussed in esophageal cancer (EC). Herein, we explored the molecular mechanism of LINC00114 via mediating enhan...

    Authors: Jianzhang Qin, Yishuai Li, Zhe Li, Xuebo Qin, Xuetao Zhou, Hao Zhang and Shujun Li
    Citation: Clinical Epigenetics 2022 14:51
  6. TIGIT is an immune checkpoint under investigation as therapeutic target. Understanding the regulation of TIGIT on an epigenetic level might support the development of companion biomarkers.

    Authors: Dennis Niebel, Anne Fröhlich, Romina Zarbl, Simon Fietz, Luka de Vos, Timo J. Vogt, Jörn Dietrich, Judith Sirokay, Pia Kuster, Gonzalo Saavedra, Susana Ramírez Valladolid, Friederike Hoffmann, Sebastian Strieth, Jennifer Landsberg and Dimo Dietrich
    Citation: Clinical Epigenetics 2022 14:50
  7. SWI/SNF complexes are major targets of mutations in cancer. Here, we combined multiple “-omics” methods to assess SWI/SNF composition and aberrations in LUAD. Mutations in lung SWI/SNF subunits were highly rec...

    Authors: Paola Peinado, Alvaro Andrades, Marta Cuadros, Maria Isabel Rodriguez, Isabel F. Coira, Daniel J. Garcia, Maria S. Benitez-Cantos, Carlos Cano, Eduardo Zarzuela, Javier Muñoz, Claudia Loidi, Monica Saiz and Pedro P. Medina
    Citation: Clinical Epigenetics 2022 14:42
  8. Long non-coding RNAs (LncRNAs) are widely known for their various functions in cancer from tumor initiation to tumor progression and metastasis. Gliomas are the most prevalent primary forms of brain tumor, cla...

    Authors: Ali Mamivand, Shiva Bayat, Abolfazl Maghrouni, Sasan Shabani, Alireza Khoshnevisan, Hiva Saffar and Mina Tabrizi
    Citation: Clinical Epigenetics 2022 14:35
  9. Epigenetic posttranslational modifications are critical for fine-tuning gene expression in various biological processes. SETD8 is so far the only known lysyl methyltransferase in mammalian cells to produce mon...

    Authors: Libo Xu, Ling Zhang, Jicheng Sun, Xindan Hu, Dhan V. Kalvakolanu, Hui Ren and Baofeng Guo
    Citation: Clinical Epigenetics 2022 14:34
  10. Age is one of the strongest risk factors for the development of breast cancer, however, the underlying etiology linking age and breast cancer remains unclear. We have previously observed links between epigenet...

    Authors: Mariya Rozenblit, Erin Hofstatter, Zuyun Liu, Tess O’Meara, Anna Maria Storniolo, Disha Dalela, Vineet Singh, Lajos Pusztai and Morgan Levine
    Citation: Clinical Epigenetics 2022 14:30
  11. We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methyl...

    Authors: Lukas Vrba, Bernard W. Futscher, Marc Oshiro, George S. Watts, Emmanuel Menashi, Charles Hu, Hytham Hammad, Daniel R. Pennington, Umamaheshwari Golconda, Hemanth Gavini, Denise J. Roe, Rachna T. Shroff and Mark A. Nelson
    Citation: Clinical Epigenetics 2022 14:28
  12. Promoter methylation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is an acknowledged predictive epigenetic marker in glioblastoma multiforme and anaplastic astrocytoma. Patients with methy...

    Authors: Sascha Tierling, Wiebke M. Jürgens-Wemheuer, Alea Leismann, Julia Becker-Kettern, Michael Scherer, Arne Wrede, David Breuskin, Steffi Urbschat, Christoph Sippl, Joachim Oertel, Walter J. Schulz-Schaeffer and Jörn Walter
    Citation: Clinical Epigenetics 2022 14:26
  13. Early detection of esophageal cancer is critical to improve survival. Whilst studies have identified biomarkers, their interpretation and validity is often confounded by cell-type heterogeneity.

    Authors: Alok K. Maity, Timothy C. Stone, Vanessa Ward, Amy P. Webster, Zhen Yang, Aine Hogan, Hazel McBain, Margaraet Duku, Kai Man Alexander Ho, Paul Wolfson, David G. Graham, Stephan Beck, Andrew E. Teschendorff and Laurence B. Lovat
    Citation: Clinical Epigenetics 2022 14:23
  14. Genome-wide association studies have identified several breast cancer susceptibility loci. However, biomarkers for risk assessment are still missing. Here, we investigated cancer-related molecular changes dete...

    Authors: Natascia Marino, Rana German, Ram Podicheti, Douglas B. Rusch, Pam Rockey, Jie Huang, George E. Sandusky, Constance J. Temm, Sandra Althouse, Kenneth P. Nephew, Harikrishna Nakshatri, Jun Liu, Ashley Vode, Sha Cao and Anna Maria V. Storniolo
    Citation: Clinical Epigenetics 2022 14:21
  15. Lymph node metastasis (LNM) is an important factor for both treatment and prognosis of early gastric cancer (EGC). Current methods are insufficient to evaluate LNM in EGC due to suboptimal accuracy. Herein, we...

    Authors: Shang Chen, Yanqi Yu, Tao Li, Weimei Ruan, Jun Wang, Quanzhou Peng, Yingdian Yu, Tianfeng Cao, Wenyuan Xue, Xin Liu, Zhiwei Chen, Jiang Yu and Jian-Bing Fan
    Citation: Clinical Epigenetics 2022 14:18
  16. Lung cancer is one of most common cancers worldwide, with a 5-year survival rate of less than 20%, which is mainly due to late-stage diagnosis. Noninvasive methods using 5-hydroxymethylation of cytosine (5hmC)...

    Authors: Xinlei Hu, Kai Luo, Hui Shi, Xiaoqin Yan, Ruichen Huang, Bi Zhao, Jun Zhang, Dan Xie and Wei Zhang
    Citation: Clinical Epigenetics 2022 14:15
  17. Non-muscle-invasive bladder cancer (NMIBC) patients receive frequent monitoring because ≥ 70% will have recurrent disease. However, screening is invasive, expensive, and associated with significant morbidity m...

    Authors: Ji-Qing Chen, Lucas A. Salas, John K. Wiencke, Devin C. Koestler, Annette M. Molinaro, Angeline S. Andrew, John D. Seigne, Margaret R. Karagas, Karl T. Kelsey and Brock C. Christensen
    Citation: Clinical Epigenetics 2022 14:14
  18. Basal-like breast cancer (BLBC) is one of the most aggressive malignant diseases in women with an increased metastatic behavior and poor prognosis compared to other molecular subtypes of breast cancer. Resista...

    Authors: Garyfallia Pantelaiou-Prokaki, Iga Mieczkowska, Geske E. Schmidt, Sonja Fritzsche, Evangelos Prokakis, Julia Gallwas and Florian Wegwitz
    Citation: Clinical Epigenetics 2022 14:7
  19. High-risk human papillomavirus (HR-HPV) infection is the main cause of cervical cancer, but additional alterations are necessary for its development. Abnormal DNA methylation has an important role in the origi...

    Authors: Jaqueline Loaeza-Loaeza, Berenice Illades-Aguiar, Oscar del Moral-Hernández, Yaneth Castro-Coronel, Marco A. Leyva-Vázquez, Roberto Dircio-Maldonado, Julio Ortiz-Ortiz and Daniel Hernández-Sotelo
    Citation: Clinical Epigenetics 2022 14:4
  20. Circulating tumor DNA (ctDNA) is a promising diagnostic and prognostic marker for many cancers and has been actively investigated in recent years. Previous studies have already demonstrated the potential use o...

    Authors: Wu-Hao Lin, Jian Xiao, Zi-Yi Ye, Da-Liang Wei, Xiao-Hui Zhai, Rui-Hua Xu, Zhao-Lei Zeng and Hui-Yan Luo
    Citation: Clinical Epigenetics 2021 13:232
  21. Deregulated methylation of tumor suppressor genes is a hallmark event in colorectal cancer (CRC) carcinogenesis. UNC5 receptors, down-regulated in various human malignancies due to epigenetic alterations, have be...

    Authors: Dong Dong, Runshi Zhang, Jie Shao, Aimin Zhang, Yichao Wang, Yunli Zhou and Yueguo Li
    Citation: Clinical Epigenetics 2021 13:225
  22. Examining immunity-related DNA methylation alterations in blood could help elucidate the role of the immune response in lung cancer etiology and aid in discovering factors that are key to lung cancer developme...

    Authors: Naisi Zhao, Mengyuan Ruan, Devin C. Koestler, Jiayun Lu, Lucas A. Salas, Karl T. Kelsey, Elizabeth A. Platz and Dominique S. Michaud
    Citation: Clinical Epigenetics 2021 13:222
  23. Colon cancer (CC) is treatable if detected in its early stages. Improved CC detection assays that are highly sensitive, specific, and available at point of care are needed. In this study, we systematically sel...

    Authors: Romy A. M. Klein Kranenbarg, Abdul Hussain Vali, Jan N. M. IJzermans, Thomas R. Pisanic II, Tza-Huei Wang, Nilofer Azad, Saraswati Sukumar and Mary Jo Fackler
    Citation: Clinical Epigenetics 2021 13:218
  24. Although radiation therapy represents a core cancer treatment modality, its efficacy is hampered by radioresistance. The effect of ionizing radiations (IRs) is well known regarding their ability to induce gene...

    Authors: Youssef Siblini, Céline Chéry, Pierre Rouyer, Jérémie Raso, Amélia Julien, Sébastien Hergalant, Aurélie François, Lina Bezdetnaya, Guillaume Vogin, Jean-Louis Guéant and Abderrahim Oussalah
    Citation: Clinical Epigenetics 2021 13:212
  25. Ten–eleven translocation methylcytosine dioxygenase 1 (TET1) is involved in DNA demethylation and transcriptional regulation, plays a key role in the maintenance of stem cell pluripotency, and is dysregulated ...

    Authors: U. Schagdarsurengin, C. Luo, H. Slanina, D. Sheridan, S. Füssel, N. Böğürcü-Seidel, S. Gattenloehner, G. B. Baretton, L. C. Hofbauer, F. Wagenlehner and T. Dansranjav
    Citation: Clinical Epigenetics 2021 13:211
  26. A shift in the proportions of blood immune cells is a hallmark of cancer development. Here, we investigated whether methylation-derived immune cell type ratios and methylation-derived neutrophil-to-lymphocyte ...

    Authors: Mehdi Manoochehri, Thomas Hielscher, Nasim Borhani, Clarissa Gerhäuser, Olivia Fletcher, Anthony J. Swerdlow, Yon-Dschun Ko, Hiltrud Brauch, Thomas Brüning and Ute Hamann
    Citation: Clinical Epigenetics 2021 13:207
  27. Lung cancer is the leading cause of cancer-related mortality. The alteration of DNA methylation plays a major role in the development of lung cancer. Methylation biomarkers become a possible method for lung ca...

    Authors: Lei Li, Zhujia Ye, Sai Yang, Hao Yang, Jing Jin, Yingying Zhu, Jinsheng Tao, Siyu Chen, Jiehan Xu, Yanying Liu, Weihe Liang, Bo Wang, Mengzhu Yang, Qiaoyun Huang, Zhiwei Chen, Weimin Li…
    Citation: Clinical Epigenetics 2021 13:185
  28. Current clinical guidelines suggest that breast cancers with low hormone receptor expression (LowHR) in 1–10% of tumor cells should be regarded as hormone receptor positive. However, clinical data show that th...

    Authors: Philipp Jurmeister, Karsten Weber, Sonia Villegas, Thomas Karn, Michael Untch, Anne Thieme, Volkmar Müller, Eliane Taube, Peter Fasching, Wolfgang D. Schmitt, Frederik Marmé, Elmar Stickeler, Bruno V. Sinn, Paul Jank, Christian Schem, Frederick Klauschen…
    Citation: Clinical Epigenetics 2021 13:184
  29. Organoids or spheroids have emerged as a physiologically relevant in vitro preclinical model to study patient-specific diseases. A recent study used spheroids of MCF10 cells to model breast cancer progression ...

    Authors: Jingwei Li, Kun Fang, Lavanya Choppavarapu, Ke Yang, Yini Yang, Junbai Wang, Ruifeng Cao, Ismail Jatoi and Victor X. Jin
    Citation: Clinical Epigenetics 2021 13:175
  30. Multiple myeloma (MM) is a malignancy of plasma cells that largely remains incurable. The search for new therapeutic targets is therefore essential. In addition to a wide panel of genetic mutations, epigenetic...

    Authors: Laurie Herviou, Sara Ovejero, Fanny Izard, Ouissem Karmous-Gadacha, Claire Gourzones, Celine Bellanger, Eva De Smedt, Anqi Ma, Laure Vincent, Guillaume Cartron, Jian Jin, Elke De Bruyne, Charlotte Grimaud, Eric Julien and Jérôme Moreaux
    Citation: Clinical Epigenetics 2021 13:174
  31. Thymic epithelial tumors (TETs) are rare neoplasms, originating from epithelial thymic cells. The oncogenic potential of these rare neoplasms is still largely undefined, and a deeper molecular characterization...

    Authors: Alessia Iaiza, Claudia Tito, Zaira Ianniello, Federica Ganci, Valentina Laquintana, Enzo Gallo, Andrea Sacconi, Silvia Masciarelli, Luciana De Angelis, Sara Aversa, Daniele Diso, Marco Anile, Vincenzo Petrozza, Francesco Facciolo, Enrico Melis, Edoardo Pescarmona…
    Citation: Clinical Epigenetics 2021 13:173
  32. Pancreatic cancer is one of the lethal cancers among solid malignancies. Pathological diagnosis of surgical margins is sometimes unreliable due to tissue shrinkage, invisible field cancerization and skipped le...

    Authors: Yuki Sunagawa, Masamichi Hayashi, Suguru Yamada, Hiroshi Tanabe, Keisuke Kurimoto, Nobutake Tanaka, Fuminori Sonohara, Yoshikuni Inokawa, Hideki Takami, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike and Yasuhiro Kodera
    Citation: Clinical Epigenetics 2021 13:172
  33. BCOR (BCL6 corepressor) is an epigenetic regulator gene involved in the specification of cell differentiation and body structure development. Recurrent somatic BCOR mutations have been identified in myelodyspl...

    Authors: Xiao Li, Feng Xu, Zheng Zhang, Juan Guo, Qi He, Lu-Xi Song, Dong Wu, Li-Yu Zhou, Ji-Ying Su, Chao Xiao, Chun-Kang Chang and Ling-Yun Wu
    Citation: Clinical Epigenetics 2021 13:169
  34. Disease progression and therapeutic resistance are hallmarks of advanced stage prostate cancer (PCa), which remains a major cause of cancer-related mortality around the world. Longitudinal studies, coupled wit...

    Authors: Romina Silva, Bruce Moran, Anne-Marie Baird, Colm J. O’Rourke, Stephen P. Finn, Ray McDermott, William Watson, William M. Gallagher, Donal J. Brennan and Antoinette S. Perry
    Citation: Clinical Epigenetics 2021 13:168
  35. In an effort to contribute to overcoming the platinum resistance exhibited by most solid tumors, we performed an array of epigenetic approaches, integrating next-generation methodologies and public clinical da...

    Authors: Javier Andrés Soto, Carlos Rodríguez-Antolín, Olga Vera, Olga Pernía, Isabel Esteban-Rodríguez, Maria Dolores Diestro, Javier Benitez, Fátima Sánchez-Cabo, Rafael Alvarez, Javier De Castro and Inmaculada Ibanez de Cáceres
    Citation: Clinical Epigenetics 2021 13:167
  36. DNA methylation, an epigenetic modification, regulates gene transcription and maintains genome stability. DNA methyltransferase (DNMT) inhibitors can activate silenced genes at low doses and cause cytotoxicity...

    Authors: Chunhong Hu, Xiaohan Liu, Yue Zeng, Junqi Liu and Fang Wu
    Citation: Clinical Epigenetics 2021 13:166
  37. DNA methylation is involved in the regulation of gene expression and phenotypic variation, but the inter-relationship between genetic variation, DNA methylation and gene expression remains poorly understood. H...

    Authors: Anna Díez-Villanueva, Mireia Jordà, Robert Carreras-Torres, Henar Alonso, David Cordero, Elisabet Guinó, Xavier Sanjuan, Cristina Santos, Ramón Salazar, Rebeca Sanz-Pamplona and Victor Moreno
    Citation: Clinical Epigenetics 2021 13:162
  38. Aberrant DNA hypomethylation of the long interspersed nuclear elements (LINE-1 or L1) has been recognized as an early event of colorectal transformation. Simultaneous genetic and epigenetic analysis of colorec...

    Authors: Carla Debernardi, Laura Libera, Enrico Berrino, Nora Sahnane, Anna Maria Chiaravalli, Cristiana Laudi, Mattia Berselli, Anna Sapino, Fausto Sessa, Tiziana Venesio and Daniela Furlan
    Citation: Clinical Epigenetics 2021 13:154

    The Correction to this article has been published in Clinical Epigenetics 2021 13:178

  39. Glioblastoma (GBM) is the most aggressive primary brain tumor, having a poor prognosis and a median overall survival of less than two years. Over the last decade, numerous findings regarding the distinct molec...

    Authors: Borja Sesé, Miquel Ensenyat-Mendez, Sandra Iñiguez, Pere Llinàs-Arias and Diego M. Marzese
    Citation: Clinical Epigenetics 2021 13:150

    The Correction to this article has been published in Clinical Epigenetics 2021 13:194

  40. In contrast to stable genetic events, epigenetic changes are highly plastic and play crucial roles in tumor evolution and development. Epithelial ovarian cancer (EOC) is a highly heterogeneous disease that is ...

    Authors: David W. Chan, Wai-Yip Lam, Fushun Chen, Mingo M. H. Yung, Yau-Sang Chan, Wai-Sun Chan, Fangfang He, Stephanie S. Liu, Karen K. L. Chan, Benjamin Li and Hextan Y. S. Ngan
    Citation: Clinical Epigenetics 2021 13:142

    The Correction to this article has been published in Clinical Epigenetics 2021 13:151

  41. Primary or acquired chemoresistance is a key link in the high mortality rate of ovarian cancer. There is no reliable method to predict chemoresistance in ovarian cancer. We hypothesized that specific methylati...

    Authors: Li-yuan Feng, Bing-bing Yan, Yong-zhi Huang and Li Li
    Citation: Clinical Epigenetics 2021 13:141
  42. Transcriptionally active chromatin is marked by tri-methylation of histone H3 at lysine 4 (H3K4me3) located after first exons and around transcription start sites. This epigenetic mark is typically restricted ...

    Authors: Tasnim H. Beacon, Geneviève P. Delcuve, Camila López, Gino Nardocci, Igor Kovalchuk, Andre J. van Wijnen and James R. Davie
    Citation: Clinical Epigenetics 2021 13:138
  43. Patients with metastatic prostate cancer (PC) are treated with androgen deprivation therapy (ADT) that initially reduces metastasis growth, but after some time lethal castration-resistant PC (CRPC) develops. A...

    Authors: Erik Bovinder Ylitalo, Elin Thysell, Mattias Landfors, Maria Brattsand, Emma Jernberg, Sead Crnalic, Anders Widmark, Magnus Hultdin, Anders Bergh, Sofie Degerman and Pernilla Wikström
    Citation: Clinical Epigenetics 2021 13:133
  44. Liver metastases can occur even in CRC patients who underwent curative surgery. While evidence suggested that adjuvant chemotherapy can help to reduce the occurrence of liver metastases for certain patients, i...

    Authors: Weihua Li, Lei Guo, Wanxiangfu Tang, Yutong Ma, Xiaonan Wang, Yang Shao, Hong Zhao and Jianming Ying
    Citation: Clinical Epigenetics 2021 13:126
  45. Resistance to DNA damaging chemotherapies leads to cancer treatment failure and poor patient prognosis. We investigated how genomic distribution of accessible chromatin sites is altered during acquisition of c...

    Authors: John Gallon, Erick Loomis, Edward Curry, Nicholas Martin, Leigh Brody, Ian Garner, Robert Brown and James M. Flanagan
    Citation: Clinical Epigenetics 2021 13:122
  46. At present, after extensive studies in the field of cancer, cancer stem cells (CSCs) have been proposed as a major factor in tumor initiation, progression, metastasis, and recurrence. CSCs are a subpopulation ...

    Authors: Saeedeh Keyvani-Ghamsari, Khatereh Khorsandi, Azhar Rasul and Muhammad Khatir Zaman
    Citation: Clinical Epigenetics 2021 13:120
  47. Mutations in the POLE gene result in an ultra-hypermutated phenotype in colorectal cancer (CRC); however, the molecular characterisation of epigenetic alterations remains unclear. We examined the genetic and epig...

    Authors: Takashi Kawai, Akihiro Nyuya, Yoshiko Mori, Takehiro Tanaka, Hiroaki Tanioka, Kazuya Yasui, Toshiaki Toshima, Fumitaka Taniguchi, Kunitoshi Shigeyasu, Yuzo Umeda, Toshiyoshi Fujiwara, Makoto Okawaki, Yoshiyuki Yamaguchi, Ajay Goel and Takeshi Nagasaka
    Citation: Clinical Epigenetics 2021 13:117
  48. Long-term stored serum is considered challenging for epigenomic analyses: as there are no cells, circulating DNA is scarce, and amplification removes epigenetic signals. Additionally, pre-analytical treatments...

    Authors: Marcin W. Wojewodzic, Magnus Leithaug, Marianne Lauritzen, Robert Lyle, Sofia Haglund, Carl-Johan Rubin, Philip A. Ewels, Tom Grotmol and Trine B. Rounge
    Citation: Clinical Epigenetics 2021 13:107